Drugs / Tradipitant
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | NEREUS | — | 2025-12-30 | fda.gov ↗ |
Trials 22 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02621385 | Nov 2015 → Feb 2016 | — | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01919944 | Aug → Nov 2013 | — | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04849559 | Feb → Sep 2021 | — | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT06804603 | Feb → Oct 2025 | obesity disorder | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT05653310 | Feb 2023 → Mar 2027 expected | dyspepsia | Xiao Jing (Iris) Wang | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT03772340 | Dec 2018 → Jun 2019 | motion sickness | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02970968 | Nov 2016 → Nov 2018 | gastroparesis | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02651714 | Jan 2016 → Aug 2017 | atopic eczema | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02004041 | Dec 2013 → Feb 2015 | atopic eczema | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00805441 | Dec 2008 → Jul 2009 | alcohol dependence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00310427 | Mar 2006 → Mar 2008 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2 | NCT00191022 | Dec 2004 → Jan 2007 | social phobia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT07446439 | Mar → Dec 2026 expected | obesity disorder | Vanda Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06836557 | Jan 2024 → Dec 2025 overdue | idiopathic gastroparesis | Vanda Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT05903924 | Sep 2023 → Apr 2024 | motion sickness | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT06138613 | Feb 2023 → Sep 2027 expected | motion sickness | Vanda Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04327661 | Nov 2021 → Apr 2023 | motion sickness | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04326426 | Apr → Aug 2020 overdue | COVID-19 | Vanda Pharmaceuticals | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT04140695 | Oct 2019 → Oct 2020 | atopic eczema | Vanda Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT04028492 | Aug 2019 → Feb 2025 | idiopathic gastroparesis | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03568331 | Jul 2018 → Dec 2019 | atopic eczema | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04474990 | — | gastroparesis | Vanda Pharmaceuticals | Available | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tradipitant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02621385 ↗ |
| Known as | LY686017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00805441 ↗ |
| Known as | VLY-686 | “VLY-686 (Tradipitant) oral capsule for 4 weeks.” NCT02970968 ↗ |
| Action | Inhibit | “LY686017 blocks Substance P from acting at the NK1 receptors.” NCT00310427 ↗1“Neurokinin 1 receptor antagonist” CHEMBL3544984 ↗ |
| Modality | Small molecule | — CHEMBL3544984 ↗ |
| Route | Oral | “50 mg administered orally on a daily basis” NCT00310427 ↗ |
| Target | TACR1 | “Neurokinin 1 receptor antagonist” CHEMBL3544984 ↗ |